EBR Systems, Inc. (ASX:EBR) has spent more than a decade developing a wireless alternative to conventional cardiac pacing, and in 2026 the company is finally being judged on commercial execution rather than clinical potential. Following United States Food and Drug Administration approval of its WiSE CRT System in April 2025, the Silicon Valley-headquartered but Australian-listed group has begun scaling implants, signing hospital purchasing contracts and building the sales infrastructure needed to reach heart failure patients who cannot be helped by existing devices.

The stock has attracted attention because it sits at the pivot point that decides most medtech stories: the shift from a single approved product to a repeatable, reimbursed commercial model. Progress so far looks encouraging, but the risks around adoption, funding and competition remain material.

From FDA approval to commercial rollout

WiSE, which stands for Wireless Stimulation Endocardially, is described by EBR as the world's only wireless, endocardial left-ventricular pacing system in clinical use. Instead of threading a pacing lead through a vein into the heart, WiSE uses a tiny electrode implanted inside the left ventricle that is powered by an ultrasound transmitter, stimulating the heart chamber directly from within. The company positions the technology for patients who have failed, or are unsuitable for, conventional cardiac resynchronisation therapy (CRT).

The device secured US Pre-Market Approval in April 2025, and the 2026 financial year has been about turning that approval into a rollout. In its June quarter update, EBR reported roughly 35 commercial cases for the period, taking cumulative implants since launch to about 72. Hospital activations reached 28 sites, purchasing contracts grew to 55 agreements, and cumulative physician training passed 100 clinicians. A purchasing agreement with HCA Healthcare, one of the largest US hospital networks with around 190 hospitals across 19 states, was highlighted by management as a milestone that should streamline procurement and widen access. These are early-stage but directionally positive numbers rather than evidence of established, at-scale demand.

Sizing the market opportunity for ASX:EBR

EBR frames its addressable opportunity at roughly US$3.6 billion, drawn from the substantial share of heart failure patients who are candidates for CRT but for whom standard coronary-sinus lead placement fails or is not feasible. Conventional CRT has been a mainstay of heart failure management for years, yet a meaningful minority of patients are considered non-responders or cannot be implanted successfully. That underserved pocket is where EBR argues WiSE has the clearest clinical rationale.

Reimbursement, the factor that ultimately governs medtech uptake in the US, has advanced. The Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment for inpatient procedures, reported at around US$63,300, alongside a Transitional Pass-Through payment for the outpatient setting. Those pathways give hospitals a defined economic basis to adopt the device while a broader, permanent coverage decision is pursued. Investors should treat the market figure as a management-defined target rather than secured revenue; penetration depends on physician behaviour, clinical evidence and payer decisions still to come.

Key catalysts ahead

The most consequential near-term catalyst is a US National Coverage Determination, with a decision the company expects around March 2027. A favourable determination would provide durable, nationwide Medicare coverage and materially de-risk the commercial model; an unfavourable or narrow one would leave adoption more dependent on the transitional payment arrangements now in place.

Clinical evidence is a second catalyst. Real-world outcomes presented at the Heart Rhythm Society's HRS2026 meeting showed a complication rate of about 10 per cent, which EBR contrasts with the 19.1 per cent recorded in its earlier SOLVE-CRT pivotal trial, arguing that outcomes improve as physicians gain experience. Continued accumulation of favourable real-world data, further hospital contracts and expansion of trained implanters are the operational signposts to watch. EBR has also flagged a fast-tracked Australian regulatory review, which could open a home market for the technology over time.

Material risks investors should weigh

The risks are considerable. Adoption and reimbursement sit at the top of the list: a slower-than-expected ramp, or a disappointing national coverage outcome, would directly threaten the revenue trajectory the market is pricing in. WiSE is also a complex, novel procedure, and any safety signal carries weight. During 2026 EBR addressed a MedSun report of complications at one hospital, noting the complication was a known, labelled risk, completing an internal investigation and reporting to the FDA. Management's framing is reasonable, but such episodes underline the scrutiny a first-of-kind implant attracts.

Funding and dilution are equally relevant. EBR is not yet profitable and remains a cash-consumptive commercial-stage business. During 2026 it raised roughly A$150 million, including a A$35.7 million retail entitlement offer priced at A$0.38 per CDI, to fund commercialisation and manufacturing scale-up, with the final tranche closing in August 2026. That strengthens the balance sheet but adds to the share count, and further raisings cannot be ruled out if the rollout takes longer than planned. Manufacturing scale-up, building repeatable production of an ultrasound-based implant, and competition from entrenched cardiac-rhythm-management players such as the major device makers round out a demanding risk profile.

A balanced view on ASX:EBR

EBR Systems (ASX:EBR) has cleared the hardest regulatory hurdle in medtech and is now executing on the equally difficult task of commercialisation. The combination of a genuine unmet clinical need, secured transitional reimbursement, growing hospital contracts and a recapitalised balance sheet gives the company a credible platform. Early implant, training and contract metrics are moving in the right direction.

Set against that are the realities of an unproven commercial model: adoption is still nascent, the pivotal national coverage decision remains months away, dilution has increased, and larger competitors dominate the broader pacing market. For readers, EBR is best understood as a company that has converted long-run clinical ambition into a live commercial test, one whose outcome will hinge on execution, evidence and reimbursement over the next several years rather than on the approval already achieved.